BEGIN:VCALENDAR
VERSION:2.0
X-WR-CALNAME;VALUE=TEXT:Thomas Beauchamp (Eli Lilly) 
PRODID:-//Harvard events data//EN
BEGIN:VEVENT
UID:event_1574631_0
SUMMARY:Thomas Beauchamp (Eli Lilly) 
DESCRIPTION:<p>	Title: Process Development of the IL-17A Inhibitor LY3509754</p><p>	<!--break--></p><p>	 </p><p>	This talk will provide a brief description of why Eli Lilly feels the development of a small </p><p>	molecule IL-17 inhibitor will provide significant benefit to patients suffering from autoimmune </p><p>	disease.</p><p>	The focus of the talk will be on the route scouting and early process development effort that was </p><p>	executed to prepare kilogram quantities of drug substance for the first human dose trial, and the</p><p>	outcome of that trial will be discussed.</p><p>	 </p><!--break-->
LOCATION:Pfizer Lecture Hall
STATUS:CONFIRMED
DTSTART:20240411T191500Z
DTEND:20240411T201500Z
END:VEVENT
END:VCALENDAR